Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.30 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29963173 | 1.00 | POLB (0.37) | POLBLMNADOT1LALDH1A1RXFP1 | |
| SCHEMBL31381531 | 0.81 | POLB (0.36) | POLBLMNAALDH1A1 | |
| SCHEMBL16332319 | 0.73 | NOTUM (0.54) | POLBALDH1A1 | |
| SCHEMBL29617149 | 0.72 | POLB (0.38) | POLBLMNAKCNJ5KCNJ3 | |
| SCHEMBL30496841 | 0.72 | POLB (0.38) | POLBKCNJ5KCNJ3 | |
| SCHEMBL9109829 | 0.72 | POLB (0.38) | POLBLMNAKCNJ5KCNJ3 | |
| SCHEMBL29963243 | 0.72 | MAPKAPK5 (0.46) | — | |
| SCHEMBL24759728 | 0.72 | MAPKAPK5 (0.46) | — | |
| SCHEMBL25309483 | 0.70 | POLB (0.36) | POLBKCNJ5KCNJ3 | |
| SCHEMBL31381803 | 0.70 | POLB (0.36) | POLBKCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545662-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-11987574-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4313970-A1 | MK2 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680056-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2022-12-22 | — | — | US | disclosed |
| WO-2022212489-A1 | MK2 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987574-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | POLB 3382/4885LMNA 4348/4885DOT1L 2675/4885 |
| US-20230373969-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | POLB 3382/4885LMNA 4348/4885DOT1L 2675/4885 |
| US-11680056-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | POLB 3382/4885LMNA 4348/4885DOT1L 2675/4885 |
| US-20230265076-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | POLB 3382/4885LMNA 4348/4885DOT1L 2675/4885 |
| US-20220402892-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, ENPP2, MAPKAPK2 | POLB 3440/4885LMNA 4260/4885DOT1L 2333/4885 |
| US-12545662-B2 | MK2 inhibitors and uses thereof | NR3C2, NR2C2, AGTR2 | POLB 2544/4885LMNA 4609/4885DOT1L 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.